ANTHEM stock
ANTHEM is in a mixed news setup around Pharmaceuticals; 3 recent stories are active but the saved quote move at +0.00% keeps the read balanced.
ANTHEM has built a mixed coverage cluster in the last 4 days. The strongest recurring theme is Pharmaceuticals, while the current weighted impact score is +7 from 1 bullish, 2 bearish, and 0 neutral stories across 2 sources.
ANTHEM is last saved at ₹883.75 with a day move of +0.00%. That quote should be read with the article tape: a positive headline only matters if price, volume, and follow-through confirm it; a negative headline matters more when it keeps repeating across multiple publishers.
Quarterly filing context will appear here after the saved-results sync has enough extracted fields. This hub keeps the permanent stock view separate from short-lived article pages, so search engines and users get one accumulated view instead of scattered programmatic summaries.
Economic Times · 6 days ago · 2 min read
Economic Times · 9 days ago · 2 min read
Economic Times · 10 days ago · 2 min read
Economic Times · 21 Aug 2026 · 2 min read
Economic Times · 19 Jun 2026 · 2 min read
How ANTHEM stacks against related names in this news cluster
ANTHEM has appeared across 3 recent stories from 2 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.
ANTHEM coverage is currently leaning bearish, with 1 bullish, 2 bearish, and 0 neutral analyzed stories in the recent window.
Recent ANTHEM coverage is clustering around Pharmaceuticals and Biotechnology. Related names showing up alongside ANTHEM include DIVISLAB, GAIL, LAURUSLABS.
Use this page as a coverage hub for ANTHEM: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.
2 recent mentions linked to ANTHEM
TopicBiotechnology1 recent mentions linked to ANTHEM
StockDIVISLABRelated news cluster with 1 links
Latest storyBullish for DIVISLAB, LAURUSLABS: Jefferies Touts CRDMO WinnersThe CRDMO segment within pharma is gaining traction due to outsourcing trends and cost efficiencies,